Clareo Health | uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
Study I: uPAR PET/CT with 68Ga-NOTA-AE105 will be evaluated as a prognostic tool in patients with non-small cell lung cancer (NSCLC) (stage IV (Ia) operable disease (Ib)) by observer-blinded readings and compared to the prognostic performance of FDG PET/CT and prognostic biomarkers as uPAR.
Furthermore, uPAR PET/CT will be evaluated in a pilot study in patients with malignant pleural mesothelioma (MPM) (Study II) and large cell neuroendocrine carcinoma of the lung (LCNEC) (Study III) and correlated with immunohistochemical uPAR expression.
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Study I
Histologically verified NSCLC (Study I)
Stage IV disease
Operable disease
The participants must be capable of understanding and giving full informed written consent
Study II
Histologically verified MPM (Study II)
The participants must be capable of understanding and giving full informed written consent
Study III
Histologically verified LCNEC (Study III)
The participants must be capable of understanding and giving full informed written consent
